tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2021 Aug 10;8(9)
fab420.
doi: 10.1093/ofid/ofab420. eCollection 2021 Sep.
Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy
Stacey Schultz-Cherry[SUP] 1 [/SUP], Maureen A McGargill[SUP] 2 [/SUP], Paul G Thomas[SUP] 2 [/SUP], Jeremie H Estepp[SUP] 3 [/SUP], Aditya H Gaur[SUP] 1 [/SUP], E Kaitlynn Allen[SUP] 2 [/SUP], Kim J Allison[SUP] 1 [/SUP], Li Tang[SUP] 4 [/SUP], Richard J Webby[SUP] 1 [/SUP], Sean D Cherry[SUP] 1 [/SUP], Chun-Yang Lin[SUP] 3 [/SUP], Thomas Fabrizio[SUP] 1 [/SUP], Elaine I Tuomanen[SUP] 1 [/SUP], Joshua Wolf[SUP] 1 5 [/SUP], SJTRC Investigative Team
Collaborators, Affiliations
Abstract
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.
Trial registration : The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.
Keywords: COVID-19; SARS-CoV-2; antibody; bamlanivimab; vaccine failure.
. 2021 Aug 10;8(9)
fab420.doi: 10.1093/ofid/ofab420. eCollection 2021 Sep.
Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy
Stacey Schultz-Cherry[SUP] 1 [/SUP], Maureen A McGargill[SUP] 2 [/SUP], Paul G Thomas[SUP] 2 [/SUP], Jeremie H Estepp[SUP] 3 [/SUP], Aditya H Gaur[SUP] 1 [/SUP], E Kaitlynn Allen[SUP] 2 [/SUP], Kim J Allison[SUP] 1 [/SUP], Li Tang[SUP] 4 [/SUP], Richard J Webby[SUP] 1 [/SUP], Sean D Cherry[SUP] 1 [/SUP], Chun-Yang Lin[SUP] 3 [/SUP], Thomas Fabrizio[SUP] 1 [/SUP], Elaine I Tuomanen[SUP] 1 [/SUP], Joshua Wolf[SUP] 1 5 [/SUP], SJTRC Investigative Team
Collaborators, Affiliations
- PMID: 34557558
- PMCID: PMC8454518
- DOI: 10.1093/ofid/ofab420
Abstract
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.
Trial registration : The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.
Keywords: COVID-19; SARS-CoV-2; antibody; bamlanivimab; vaccine failure.